1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan Q1 Roundup: High Hopes For Leqembi And Veozah, Forex Give And Take

Entyvio SC In Wings

 
• By Lisa Takagi

Daiichi Sankyo, Chugai and Shionogi all marked double-digit revenue growth in the fiscal first quarter, while Astellas and Takeda saw some slow down. New products including Veozah and Leqembi buoyed performances, while the the expected upcoming US approval of a subcutaneous formulation may help restore Entyvio’s growth trajectory.

Takeda, Astellas, Chugai, Daiichi Sankyo, Eisai, Shionogi announced its quarterly performance.
major Japanese pharma firms announce fiscal Q1 performance • Source: Shutterstock

The continued weakness of the yen had both a positive and negative impact on sales and costs outside Japan, respectively, as major Japanese firms reported their financial results for the fiscal first quarter ended 30 June.

Daiichi Sankyo Co., Ltd., Shionogi & Co. Ltd. and Chugai Pharmaceutical Co., Ltd. (which reported calendar first-half results) all logged double-digit growth, although Takeda Pharmaceutical Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.